MAP2K7 and neoplasm: RMC-4630 is also being tested in combination with combimetinib, a MEK inhibitor, and a recent update has shown some preliminary evidence of anti-tumour activity in KRAS-mutant colorectal cancer with tumour reduction in 37.5% of patients (3/8) [64].